Understand the Difference Between Primary and Secondary Outcomes in Less Than 5 Minutes

(5:21)

How to Analyze Primary Sources and Secondary Sources

(4:43)

Primary analysis of TROPHY-U-01 Cohort 2

(35)

Primary Source Analysis Tutorial

(3:17)

Primary analysis of HAVEN 7: emicizumab prophylaxis in infants with severe hemophilia A

(8:37)

How to Analyze Primary Sources in History

(15:)

Primary analysis of the Phase II PILOT study: liso-cel as second-line therapy for R/R LBCL

(6:13)

Analyzing Primary Sources

(4:25)

XAG/USD Price Forecast Today, Technical Analysis (January 13): Silver Falls to a Five-day Low

(2:10)

Introduction to Primary Source Analysis

(5:34)

Craig Portell, MD: Primary Analysis and Results of BR-VEN for Initial Treatment of MCL

(8:)

Primary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCL

(2:19)

Primary analysis of MURANO study data for R/R CLL

(4:1econd)

Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL

(1:12)

GLOW: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in CLL

(3:34)

Primary analysis of Pola-G-Len: favorable findings for R/R follicular lymphoma

(2:25)

How to write a Primary Source Analysis

(2:31)

Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

(3:49)

Primary analysis of the randomized phase II trial of VRd and elotuzumab for ND HRMM: SWOG-1211

(3:37)

2024 Primary analysis

(3:13)